arXivDaily arXiv每日学术速递 周一至周五更新
arXiv 2312.12482q-bio.QMcs.LG
收藏

新视野:从实验室到临床,生成式AI开创制药研发新纪元——行业视角

New Horizons: Pioneering Pharmaceutical R&D with Generative AI from lab to the clinic -- an industry perspective

Bayer AG(拜耳股份公司);Capgemini Engineering(凯捷工程);Capgemini(凯捷)

Guy Doron, Sam Genway, Mark Roberts, Sai Jasti

AI总结:

本文从行业视角,以三视野框架审视生成式AI在制药研发全价值链中的应用,涵盖当前影响、近期机遇与长期转型,并为研发领导者提出战略建议,强调以可持续发展为核心,加速从发现到临床的闭环。

摘要:

生成式人工智能的快速发展正在重塑各行业研发的战略愿景。制药研发面临的独特挑战将见证生成式AI在从早期发现到监管批准的整个价值链中创造价值。本文回顾了这些挑战,并采用三视野方法来探讨已经产生影响的生成式AI应用、即将到来的颠覆性机遇,以及将塑造行业未来的长期转型。本文评述了部分应用在提升生产力、加快时间线、提高研究、数据和决策质量,以及支持行业可持续发展方面的潜力。文章为当今正在制定生成式AI战略的制药研发领导者提供了建议,这些建议将为从技术中获取实际价值和保障未来增长奠定基础。生成式AI如今正提供新的高效途径来访问和整合组织数据以推动生产力。接下来,这一影响将触及临床开发,提升患者体验,推动运营效率,并释放数字创新以更好地应对未来的疾病负担。展望最远的地平线,快速获取丰富的多组学数据(这些数据捕捉了“生命语言”),结合下一代AI技术,将使组织能够通过从实验室到床边的快速自动化假设生成与测试,闭环管线各阶段。这为以可持续发展为核心的研发未来提供了愿景,缩短了时间线并减少了对资源的依赖,同时为患者带来治疗不治之症并最终治愈疾病的新希望。

英文摘要:

The rapid advance of generative AI is reshaping the strategic vision for R&D across industries. The unique challenges of pharmaceutical R&D will see applications of generative AI deliver value along the entire value chain from early discovery to regulatory approval. This perspective reviews these challenges and takes a three-horizon approach to explore the generative AI applications already delivering impact, the disruptive opportunities which are just around the corner, and the longer-term transformation which will shape the future of the industry. Selected applications are reviewed for their potential to drive increase productivity, accelerate timelines, improve the quality of research, data and decision making, and support a sustainable future for the industry. Recommendations are given for Pharma R&D leaders developing a generative AI strategy today which will lay the groundwork for getting real value from the technology and safeguarding future growth. Generative AI is today providing new, efficient routes to accessing and combining organisational data to drive productivity. Next, this impact will reach clinical development, enhancing the patient experience, driving operational efficiency, and unlocking digital innovation to better tackle the future burden of disease. Looking to the furthest horizon, rapid acquisition of rich multi-omics data, which capture the 'language of life', in combination with next generation AI technologies will allow organisations to close the loop around phases of the pipeline through rapid, automated generation and testing of hypotheses from bench to bedside. This provides a vision for the future of R&D with sustainability at the core, with reduced timescales and reduced dependency on resources, while offering new hope to patients to treat the untreatable and ultimately cure diseases.

机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。

↑